M6223
Phase 2Small molecule
EMD Serono Research & Development Institute, Inc.M6223 is one of 4 small molecule programs targeting Locally Advanced or Metastatic Urothelial Carcinoma. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
4 competitors in Locally Advanced or Metastatic Urothelial Carcinoma
#DrugCompanyPhaseTrials
1TRODELVY
GileadPhase 2
Bavencio
EMD SeronoPhase 2
NKTR-255
NNektar Therapeutics
Phase 2
M6223
EMD Serono Research & Development Institute, Inc.Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Locally Advanced or Metastatic Urothelial Carcinoma1 trial
A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination With Other AntiTumor Agents as a Maintenance Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress With First Line Platinum-Containing Chemotherapy (JAVELIN Bladder Medley)
Active, not recruiting·EMD Serono Research & Development Institute, Inc.·Phase 2·NCT05327530·256 enrolled
EMD Serono Research & Development Institute, Inc.·Phase 2·NCT05327530·256 enrolledUnspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for M6223. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details